Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07216430 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of wSp Vaccine in Young Children
A Phase 2 study of Acute Otitis Media (AOM), sponsored by Serum Life Science Europe.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 320
- Enrollment target
- 4
- Study locations
NCT07216430: Recruiting Phase 2 study of Acute Otitis Media (AOM), sponsored by Serum Life Science Europe.
NCT07216430 is a Phase 2 study of Acute Otitis Media (AOM) that is actively recruiting participants, run by Serum Life Science Europe. The registered enrollment target is 320 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (141% higher). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07216430, a Phase 2 study of Acute Otitis Media (AOM), is actively recruiting participants, sponsored by Serum Life Science Europe.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 320 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this clinical trial is to evaluate whether the wSp vaccine can prevent nasopharyngeal colonization by pneumococcal bacteria in healthy young children who have received routine PCV20 vaccination. The main questions it aims to answer are: Does wSp vaccine reduce pneumococcal colonization in the nose? Does wSp vaccine safely stimulate the immune system to produce antibodies and protective immune responses? Researchers will compare children receiving two injections of wSp vaccine to those receiving saline placebo to see if wSp vaccine reduces colonization and boosts immunity. Participants will: Receive two injections of either wSp or saline at 7 and 9 months of age. Have blood samples taken at 6 and 12 months to measure immune responses. Have nasal swabs collected at several time points and during infections from 6-24 months. Be monitored for ear infections, respiratory illnesses, and other pneumococcal-related infections.
Primary Outcome
Occurrence of a culture-confirmed S. pneumoniae of differing serotypes in the nasopharynx (as defined by isolation of S. pneumoniae from NP samples) * at four healthy visits, child age 12, 15, 18 and 24 months old and/or * 14 days after second vaccine dose through 24 months of age, at AOM, LRTI, and URTI visits throughout study participation.
Conditions Studied
Interventions
- BIOLOGICAL wSp vaccine
- BIOLOGICAL Saline (0.9% NaCl)
Study Locations (4)
New York
- Western New York Geneva Pediatrics - Rochester
- Bay Creek Pediatrics - Rochester
- Rochester Medical Group General Pediatric Associates - Rochester
- Panorama Pediatrics - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2025-09-29 |
| Est. Completion | 2029-06 |
| Phase | Phase 2 |
What NCT07216430 shows while recruiting
NCT07216430 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (141% higher).
The record links to 1 condition, with Acute Otitis Media (AOM) appearing as the primary indexed condition, and to 2 interventions - of which wSp vaccine is the first listed.
NCT07216430 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07216430 about?
NCT07216430 is a clinical study titled "Safety and Efficacy of wSp Vaccine in Young Children". The goal of this clinical trial is to evaluate whether the wSp vaccine can prevent nasopharyngeal colonization by pneumococcal bacteria in healthy young children who have received routine PCV20 vaccination. The main questions it aims to answer are: Does wSp vaccine reduce pneumococcal colonization...
What is the current status of trial NCT07216430?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 320 participants. The study started on 2025-09-29. Estimated completion is 2029-06.
What conditions does trial NCT07216430 study?
This clinical trial studies the following conditions: Acute Otitis Media (AOM).
What interventions are being tested in trial NCT07216430?
The interventions under investigation include: wSp vaccine (BIOLOGICAL), Saline (0.9% NaCl) (BIOLOGICAL).
Who is sponsoring clinical trial NCT07216430?
This trial is sponsored by Serum Life Science Europe, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07216430 being conducted?
This trial has 4 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Otitis Media (AOM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07216430's enrollment target sits among peer trials
320 152nd of 2000 higher than 1,848 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI